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Neurotoxicity Secondary to Intraperitoneally Administered
Cefepime: Report of Two Cases
Sze-Kit Yuen, Sai-Ping Yong, Hing-Sum Tsui
Cefepime is a broad-spectrum antibiotic used successfully as empirical monotherapy in patients with continuous
ambulatory peritoneal dialysis (CAPD) peritonitis. Unfortunately, current intraperitoneal dosage recom-
mendations are based on clinical experience rather than solid pharmacokinetic knowledge. We report two
cases of cefepime-related confusion in CAPD peritonitis treated with intraperitoneal cefepime at a commonly
used dosage. High peritoneal membrane transport characteristics and deteriorating residual renal function may
alert clinicians to the risk of cefepime-induced neurotoxicity. Pharmacokinetic data are essential for rational
prescription when the drug is to be administered intraperitoneally. [Hong Kong J Nephrol 2004;6(2):106–8]
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INTRODUCTION
Cefepime is a fourth-generation cephalosporin with
broader spectrum antimicrobial activity than most
third-generation cephalosporins. In addition to retaining
good activity against Gram-positive organisms, cefe-
pime demonstrates expanded Gram-negative coverage
when compared with other widely used cephalosporins
such as ceftazidime [1]. Its versatility makes it an ideal
choice as empirical monotherapy for the treatment of
continuous ambulatory peritoneal dialysis (CAPD)
peritonitis while waiting for bacterial culture results [2].
Despite the lack of pharmacokinetic data, cefepime
has been successfully administered intraperitoneally to
treat CAPD peritonitis [2,3]. Our center has developed
a similar protocol for the empirical treatment of CAPD
peritonitis in patients who are non-anuric. The standard
regimen involves a loading dose of 1 g followed by a
maintenance dose of 250 mg four times per day, all
delivered intraperitoneally during each 2 L dwell. We
report two cases of neurotoxicity related to the use of
cefepime in this regimen.
CASE REPORTS
Case 1
A 44-year-old housewife with diabetic nephropathy on
CAPD since August 2002 suffered from her first episode
of CAPD peritonitis in November 2002. She was given
cefepime for 4 days according to our standard regimen,
before switching to oral levofloxacin according to bac-
terial sensitivity (dialysate grew Acinetobacter sp). She
was cured with no side effects.
In February 2003, annual assessment showed a
residual creatinine clearance of 1.39 mL/min/1.73 m2.
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A peritoneal equilibration test (PET) classified her
as a “high average” transporter (dialysate to plasma
creatinine ratio at 4 hours, 0.81).
In May 2003, she was admitted again for CAPD
peritonitis and was started on cefepime empirically
according to our standard regimen. Cefepime was
changed to intraperitoneal cefuroxime 2 days later,
according to the culture sensitivity result (dialysate grew
Enterobacter sp). The treatment was successful, without
any complications.
She was admitted in October 2003 for abdominal
pain and cloudy dialysate. The dialysate white cell count
was 3,280/mm3 with 88% polymorphs. She was treated
for CAPD peritonitis and empirically started on our
standard regimen of intraperitoneal cefepime. The
dialysate cleared up after 4 days of treatment.
On day 5, she became dull and showed subtle
dysarthria. She was arousable with full orientation to
time, place, and person. She was afebrile and her neck
was supple. There was generalized weakness and hy-
poreflexia. Plantar jerks were downward. There were
no other demonstrable neurologic signs. Plasma urea
concentration was 23.6 mmol/L and creatinine con-
centration was 1,117 μmol/L. Electrolytes, including
calcium, were normal. Plain computed tomography
(CT) brain scan was normal.
Her condition deteriorated over the next 2 days. On
day 7, she had become confused, disorientated, and
obtunded. She required physical restraint and insertion
of a nasogastric tube for feeding. The dialysate grew
Klebsiella and Enterobacter species, both sensitive to
cefepime. Cefepime-related neurotoxicity was sus-
pected and the dosage of intraperitoneal cefepime was
halved to 125 mg four times per day.
Her condition improved markedly over the next 2
days. On day 9, she was fully orientated with no residual
neurologic deficit. The nasogastric tube was removed.
The prompt clinical response and dialysate culture
sensitivity results prompted us to continue cefepime
monotherapy at the reduced dose. This episode of
peritonitis was cured without relapse after a 2-week
course of cefepime. Subsequently, her residual re-
nal creatinine clearance was reduced to 0.02 mL/min/
1.73 m2.
Case 2
A 65-year-old housewife with diabetic nephropathy was
started on CAPD in February 2002. PET in June 2002
classified her as a “high” transporter (dialysate to
plasma creatinine ratio at 4 hours, 0.87). Residual re-
nal creatinine clearance was 2.31 mL/min/1.73 m2 in
October 2003.
She was admitted in March 2004 for her first epi-
sode of CAPD peritonitis. She was treated with intra-
peritoneal cefepime according to our standard regi-
men. Her dialysate started to clear up from day 2.
She became less talkative on day 3, despite being
fully conscious and able to give her name. There were
no focal neurologic signs. Plasma urea concentration
was 24.2 mmol/L and creatinine concentration was
853 μmol/L. Electrolytes and thyroid function test were
normal. Urgent CT brain scan showed a tiny hypoden-
sity over the right corona radiata, which was considered
irrelevant to the whole clinical picture.
On day 4, she became totally confused, requiring
restraint and nasogastric tube feeding. She demon-
strated only occasional, incomprehensible speech.
Lumbar puncture yielded a sterile specimen with nor-
mal biochemistry and no white blood cells. Cefepime-
related confusion was suspected and therapy was
changed to intraperitoneal cefazolin. The dialysate later
grew coagulase-negative Staphylococcus sensitive to
penicillin and cloxacillin.
Her confusion gradually resolved over the next 3
days. By day 7, she had become fully orientated,
although she still complained of malaise. On day 9,
she was able to walk with a frame. After an extra week
of rehabilitation, she was able to walk unaided, with
no residual neurologic deficit. Her CAPD peritonitis
was cured with a course of intraperitoneal cefazolin.
DISCUSSION
The conventional management of CAPD peritonitis has
been intraperitoneal administration of antibiotics, and
treatment protocols are often derived from clinical ex-
perience rather than pharmacokinetic or pharmacolo-
gic data [4]. The pharmacokinetics of intravenous
cefepime have been studied in patients with severe renal
insufficiency [5] and those undergoing CAPD [6]. In
contrast, the pharmacokinetics of intraperitoneal
cefepime have not been so well described.
In the treatment of CAPD peritonitis, the importance
of bactericidal plasma versus intraperitoneal con-
centrations of antibiotic is uncertain [4]. In general, a
drug moves rapidly from the peritoneal space to the
systemic circulation, in contrast to the slow appearance
of the same drug in the peritoneal dialysate when
administered by the intravenous route. This is termed
unidirectional drug transport [7]. It can be inferred that
intraperitoneal administration of cefepime leads to
initial peritoneal fluid drug levels that cannot be
achieved by an equivalent dose administered intra-
venously. Dialysate effluent drug measurement is thus
particularly important in any pharmacokinetic study
of patients on CAPD. In a single case report, intra-
peritoneally administered cefepime led to sustained
therapeutic plasma levels. However, the dialysate
effluent drug level was not measured [8].
Nevertheless, intraperitoneal cefepime, administer-
ed at a loading dose of 2 g followed by a daily main-
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tenance dose of 1 g, has been used as effective empirical
monotherapy for CAPD peritonitis [2,3]. In our center,
a similar regimen has been used very successfully over
the past 2 years.
Despite a good safety profile, adverse central
nervous system reactions due to cefepime have proba-
bly been under-recognized [9]. Possible side effects in-
clude confusion with temporospatial disorientation,
myoclonus, and seizures. Both advanced age and renal
insufficiency are common risk factors for neurotoxicity
[9–11]. Apart from a case of CAPD peritonitis treated
accidentally with a high daily dose of 4 g [9], intraperi-
toneal cefepime has been reported to be safe and well
tolerated [2]. To our knowledge, this is the first report
of neurotoxicity developing in patients treated with 1 g
intraperitoneal cefepime daily.
Our first case had been given intraperitoneal
cefepime twice previously without any neurologic toxic
effect. We speculate that the better-preserved residual
renal function, coupled with a lower cumulative dose,
might be the underlying reason.
The diagnosis of cefepime-related neurotoxicity
may be questioned without measuring serum and
cerebrospinal fluid (CSF) drug levels (assay not
available in Hong Kong). However, a presumptive
clinical diagnosis can often be made in a susceptible
patient with a typical clinical picture and complete
recovery on withdrawal of the drug [12,13]. Although
electroencephalographic (EEG) abnormalities have
been described [9–11], the findings are far from
universal or diagnostic. Unfortunately, EEG services
were not available to our patients and we had to rely
heavily on our clinical judgment. Of note, cefepime
was continued in the first case, albeit at a lowered dose.
Based on the Naranjo adverse drug reaction probability
scale [14], both of our cases were classified as “possible
adverse drug reactions”.
Our patients might be particularly susceptible to the
toxicity of intraperitoneally-administered cefepime.
Case 1 was a high-average transporter while Case 2
was a high transporter. It is possible that they attained
higher serum bioavailability compared with low trans-
porters. Increased membrane permeability during peri-
tonitis [7], impaired active transport of cephalosporins
from CSF to blood [9,10], decreased protein binding
in uremia, and decreased drug clearance in uremia [12]
all predispose these patients to neurotoxicity.
From July 2002 to June 2004, we treated more than
70 episodes of CAPD peritonitis with our empirical
regimen of intraperitoneal cefepime. Cefepime-related
neurotoxicity is, thus, uncommon but should be borne
in mind, particularly in patients who are anuric.
Theoretically, the pharmacokinetic data of parenteral
cefepime are totally irrelevant when the drug is admin-
istered intraperitoneally. Pharmacokinetic studies on
intraperitoneally-administered cefepime in patients
with CAPD peritonitis are essential in guiding rational
prescription at correct dosages.
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